Log in

Concert Pharmaceuticals Stock Forecast, Price & News

+0.35 (+3.18 %)
(As of 11/27/2020 12:00 AM ET)
Today's Range
Now: $11.37
50-Day Range
MA: $11.03
52-Week Range
Now: $11.37
Volume78,315 shs
Average Volume152,080 shs
Market Capitalization$348.48 million
P/E RatioN/A
Dividend YieldN/A
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company also have license agreement with Cipla Technologies. Concert Pharmaceuticals was founded in 2006 and is headquartered in Lexington, Massachusetts.
Read More
Concert Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.68 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CNCE



Sales & Book Value

Annual Sales$1.08 million
Book Value$4.17 per share


Net Income$-78,170,000.00
Net Margins-921.38%


Market Cap$348.48 million
Next Earnings Date2/25/2021 (Estimated)
+0.35 (+3.18 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for CNCE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions

How has Concert Pharmaceuticals' stock been impacted by COVID-19?

Concert Pharmaceuticals' stock was trading at $8.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CNCE stock has increased by 36.2% and is now trading at $11.37.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Concert Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Concert Pharmaceuticals

What stocks does MarketBeat like better than Concert Pharmaceuticals?

Wall Street analysts have given Concert Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Concert Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Concert Pharmaceuticals' next earnings date?

Concert Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Concert Pharmaceuticals

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) announced its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.15. Concert Pharmaceuticals had a negative return on equity of 55.20% and a negative net margin of 921.38%.
View Concert Pharmaceuticals' earnings history

What price target have analysts set for CNCE?

6 Wall Street analysts have issued 1 year price targets for Concert Pharmaceuticals' shares. Their forecasts range from $11.00 to $30.00. On average, they expect Concert Pharmaceuticals' stock price to reach $21.40 in the next twelve months. This suggests a possible upside of 88.2% from the stock's current price.
View analysts' price targets for Concert Pharmaceuticals

Who are some of Concert Pharmaceuticals' key competitors?

What other stocks do shareholders of Concert Pharmaceuticals own?

Who are Concert Pharmaceuticals' key executives?

Concert Pharmaceuticals' management team includes the following people:
  • Mr. Richard H. Aldrich M.B.A., Mba, Co-Founder & Chairman (Age 66, Pay $83.52k)
  • Dr. Roger D. Tung, Co-Founder, CEO, Pres & Exec. Director (Age 60, Pay $882.85k)
  • Mr. Marc A. Becker, CFO & Principal Accounting Officer (Age 48, Pay $559.68k)
  • Dr. James V. Cassella, Chief Devel. Officer (Age 65, Pay $667.08k)
  • Ms. Nancy Stuart, Chief Operating Officer (Age 62)
  • Ms. Justine E. Koenigsberg, Sr. VP of Corp. Communications and Investor Relations
  • Mr. Jeffrey A. Munsie, Chief Legal Officer & Corp. Sec. (Age 43)
  • Dr. Ian Robert Silverman J.D., Ph.D., Sr. Legal Advisor (Age 67)

What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

Who are Concert Pharmaceuticals' major shareholders?

Concert Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.12%), Ingalls & Snyder LLC (4.59%), Point72 Asset Management L.P. (2.53%), State Street Corp (1.67%), Connor Clark & Lunn Investment Management Ltd. (1.12%) and Sphera Funds Management LTD. (1.01%). Company insiders that own Concert Pharmaceuticals stock include Bvf Partners L P/Il, Heek Christi Van, Nancy Stuart, Peter Barton Hutt and Thomas G Auchincloss.
View institutional ownership trends for Concert Pharmaceuticals

Which major investors are selling Concert Pharmaceuticals stock?

CNCE stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Acadian Asset Management LLC, Wells Fargo & Company MN, WINTON GROUP Ltd, Ingalls & Snyder LLC, Dupont Capital Management Corp, Connor Clark & Lunn Investment Management Ltd., and JPMorgan Chase & Co..
View insider buying and selling activity for Concert Pharmaceuticals

Which major investors are buying Concert Pharmaceuticals stock?

CNCE stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., GSA Capital Partners LLP, Arrowstreet Capital Limited Partnership, Squarepoint Ops LLC, Jane Street Group LLC, AXA S.A., State Street Corp, and BNP Paribas Arbitrage SA. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Heek Christi Van, and Thomas G Auchincloss.
View insider buying and selling activity for Concert Pharmaceuticals

How do I buy shares of Concert Pharmaceuticals?

Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Concert Pharmaceuticals' stock price today?

One share of CNCE stock can currently be purchased for approximately $11.37.

How big of a company is Concert Pharmaceuticals?

Concert Pharmaceuticals has a market capitalization of $348.48 million and generates $1.08 million in revenue each year. The biotechnology company earns $-78,170,000.00 in net income (profit) each year or ($3.29) on an earnings per share basis. Concert Pharmaceuticals employs 70 workers across the globe.

What is Concert Pharmaceuticals' official website?

The official website for Concert Pharmaceuticals is www.concertpharma.com.

How can I contact Concert Pharmaceuticals?

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.